全文获取类型
收费全文 | 905篇 |
免费 | 50篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 9篇 |
妇产科学 | 9篇 |
基础医学 | 95篇 |
口腔科学 | 20篇 |
临床医学 | 46篇 |
内科学 | 224篇 |
皮肤病学 | 8篇 |
神经病学 | 26篇 |
特种医学 | 32篇 |
外科学 | 166篇 |
综合类 | 9篇 |
预防医学 | 10篇 |
眼科学 | 24篇 |
药学 | 106篇 |
肿瘤学 | 168篇 |
出版年
2023年 | 6篇 |
2022年 | 13篇 |
2021年 | 32篇 |
2020年 | 18篇 |
2019年 | 15篇 |
2018年 | 27篇 |
2017年 | 26篇 |
2016年 | 24篇 |
2015年 | 14篇 |
2014年 | 32篇 |
2013年 | 32篇 |
2012年 | 49篇 |
2011年 | 60篇 |
2010年 | 37篇 |
2009年 | 25篇 |
2008年 | 36篇 |
2007年 | 50篇 |
2006年 | 43篇 |
2005年 | 33篇 |
2004年 | 39篇 |
2003年 | 43篇 |
2002年 | 30篇 |
2001年 | 16篇 |
2000年 | 27篇 |
1999年 | 19篇 |
1998年 | 6篇 |
1997年 | 8篇 |
1996年 | 4篇 |
1994年 | 5篇 |
1992年 | 7篇 |
1991年 | 18篇 |
1990年 | 6篇 |
1989年 | 8篇 |
1988年 | 16篇 |
1987年 | 14篇 |
1986年 | 9篇 |
1985年 | 13篇 |
1984年 | 7篇 |
1983年 | 9篇 |
1982年 | 3篇 |
1979年 | 8篇 |
1978年 | 13篇 |
1977年 | 6篇 |
1975年 | 12篇 |
1974年 | 5篇 |
1973年 | 3篇 |
1971年 | 3篇 |
1969年 | 7篇 |
1968年 | 3篇 |
1965年 | 3篇 |
排序方式: 共有957条查询结果,搜索用时 734 毫秒
31.
32.
33.
Disseminated toxoplasmosis after hematopoietic stem cell transplantation showing unusual magnetic resonance images
下载免费PDF全文
![点击此处可从《Transplant infectious disease》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Takahiro Tateno Masahiro Onozawa Junichi Hashiguchi Takashi Ishio Sayaka Yuzawa Satomi Matsuoka Mizuha Kosugi‐Kanaya Kohei Okada Souichi Shiratori Hideki Goto Taichi Kimura Junichi Sugita Masao Nakagawa Daigo Hashimoto Kaoru Kahata Katsuya Fujimoto Tomoyuki Endo Takeshi Kondo Shinya Tanaka Satoshi Hashino Takanori Teshima 《Transplant infectious disease》2017,19(4)
We herein report a patient who had disseminated toxoplasmosis after hematopoietic stem cell transplantation showing atypical clinical presentation and neuroimaging. Parkinsonism symptoms such as muscle rigidity, bradykinesia, tremor, and postural instability were initial manifestations. Magnetic resonance imaging showed diffuse symmetrical lesions of bilateral basal ganglia lacking ringed enhancement. Post‐mortem analysis revealed multiple tachyzoites of Toxoplasma gondii in the basal ganglia, mid brain, cerebellum, and cardiac muscle. 相似文献
34.
35.
Satoshi Higuchi Ayako Okada Morio Shoda Daigo Yagishita Satoshi Saito Miwa Kanai Shohei Kataoka Kyoichiro Yazaki Hiroaki Tabata Hideki Kobayashi Wataru Shoin Takahiro Okano Koji Yoshie Koichiro Ejima Koichiro Kuwahara Nobuhisa Hagiwara 《老年心脏病学杂志》2021,18(7):505-513
BackgroundManagement of pacemaker (PM) infections among advanced aged patients possesses particular clinical challenges due to higher rates of concurrent cardiovascular disease and medical comorbidities. Novel leadless cardiac pacemakers (LCPs) may provide new opportunities for better management options in this population, however, there is limited data especially in Asian populations to guide the decision making.MethodsWe reviewed 11 octogenarians (median age: 86 [minimum 82–maximum 90] years; male: 73%; median body mass index (BMI): 20.1 kg/m2) who received Micra Transcatheter Pacing System (Medtronic Inc, Minneapolis, MN) implantations following transvenous lead extractions (TLEs) for PM infections. ResultsAll patients had more than two medical comorbidities (average 3.7 comorbidities). The indications for LCP implantations were atrioventricular block in four patients, atrial fibrillation bradycardia in five, and sinus node dysfunction in two. Eight patients (73%) were bridged with temporary pacing using active fixation leads (median interval of 14.0 days), while one with severe dementia underwent a concomitant LCP implantation and TLE during the same procedure. Successful TLEs and LCP implantations were successfully accomplished in all without any complications. The median time from the TLE procedure to discharge was 22 days (minimum 7–maximum 136). All patients remained free of infections during a mean follow-up period of 17.2 ± 6.5 months.ConclusionsLCP implantations were safe and effective after removing the entire infectious PM system in all octogenarians. The novel LCP technology may offer an alternative option for considering a re-implantation strategy after transvenous PM infections in elderly patients, particularly those with severe frailty and PM dependency.The incidence of cardiac pacemaker (PM) infections among patients with an advanced age has been increasing owing to the continually widening indications and growing number of generator replacements.[1–3] In current clinical practice, there is a class l indication for removing all hardware in the case of a proven or suspected device infection, and after a recovery window, a new conventional PM is implanted in PM dependent patients.[1,4,5] However, this management for the elderly population is one of the most sensitive issues, since they possess particular clinical challenges due to higher rates of concurrent cardiovascular disease and medical comorbidities.[6–10]Recently, the implantation of a Micra Transcatheter Pacing System (Medtronic Inc, Minneapolis, MN) has emerged as a new option for PM re-implantations after the removal of infectious PMs.[11–17] Without the use of leads and a device pocket, this leadless cardiac pacemaker (LCP) potentially reduces the risk of pocket infections and lead associated endocarditis.[16,17] However, there have not been enough data supporting the feasibility of leadless PM implantations following the removal of infectious PMs in people with an older age, particularly in octogenarians. Furthermore, there has been no data regarding those therapeutic strategies in Asian populations who have a low body mass index (BMI) and are at a higher risk of a transvenous lead extraction (TLE) procedure. Therefore, in this case series, we sought to characterize the procedure for LCP implantations following TLEs of infected PMs in octogenarians at 2 Japanese high-volume centers. 相似文献
36.
Onishi Y Mori S Kusumoto S Sugimoto K Akahane D Morita-Hoshi Y Kim SW Fukuda T Heike Y Tanosaki R Tobinai K Takaue Y 《International journal of hematology》2007,85(3):256-263
We investigated the feasibility of reduced-intensity conditioning with 4 Gy total body irradiation, fludarabine (30 mg/m2 for 6 days), and busulfan (4 mg/kg for 2 days) for bone marrow transplantation from a serologically HLA-matched unrelated donor. Seventeen adult patients (median age, 55 years; range, 27-67 years) with various hematologic malignancies (6 in remission, 11 not in remission) were treated. Successful engraftment was achieved in all patients at a median of day 18 (range, day 14-35) after transplantation, although subsequent secondary graft failure was observed in 2 patients. The cumulative incidence of acute graft-versus-host disease (GVHD) of grades II to IV at day 100 was 48%. With a median follow-up of 286 days (range, 56-687 days), the rates of 1-year overall survival, 100-day nonrelapse mortality, and 1-year nonrelapse mortality were 41%, 14%, and 46%, respectively. Eleven patients died, and the causes of death were relapse (n = 4), pulmonary complications (n = 4), acute GVHD (n = 2), and sepsis (n = 1). The remaining 6 patients (at transplantation, 2 were in remission, and 4 were not in remission) are currently still in remission. These results suggest that this regimen reduces the risk of graft failure, but further studies are needed to ameliorate transplantation-related toxicities, primarily GVHD and/or pulmonary complications. 相似文献
37.
38.
Tanaka S Harada M Mine T Noguchi M Gohara R Azuma K Tamura M Yamada A Morinaga A Nishikori M Katagiri K Itoh K Yamana H Hashimoto T 《Journal of immunotherapy (Hagerstown, Md. : 1997)》2003,26(4):357-366
Identification of antigenic peptides expressed on cancer cells enables us to treat cancer patients with peptide-based immunotherapy. Although optimal protocols for peptide-based vaccines have not yet been elucidated, boosting the immune system could be a better approach than priming the immune system to elicit prompt and potent peptide-specific T-cell responses in cancer patients. With this possibility in mind, the authors undertook a clinical trial in which cancer patients were vaccinated with peptides (maximum 4) after confirmation of pre-existing peptide-specific cytotoxic T-lymphocyte (CTL) precursors in the periphery. Fourteen patients (seven with melanoma and seven with other types of cancer) positive for either HLA-A24 or HLA-A2 were enrolled in this study. Fourteen and 16 peptides were used to screen for HLA-A24+ and HLA-A2+ patients, respectively. The vaccination was well tolerated, and the only adverse effects were local pain and fever. Kinetic analysis revealed that peptide-reactive CTLs increased after peptide vaccination in 7 of 14 patients. Immunoglobulin G (IgG) reactive to the administered peptides was detected in 2 patients before vaccination, although it became detectable in 8 of the other 12 patients after the peptide vaccination. Stable disease for more than 6 months was observed in five patients (one with melanoma and four with other types of cancer); all of these patients showed increased levels of peptide-specific IgG. These results indicate that peptide vaccination of patients showing evidence of pre-existing peptide-specific CTL precursors can be applied in further clinical trials aimed at the treatment of melanoma and other types of cancer. 相似文献
39.
Yamana H 《Nihon Geka Gakkai zasshi》2002,103(4):376-380
Recent progress in gene technology has clarified the existence of some cancer-rejection genes and peptides such as MAGE, MART, etc. Many clinical trials with cancer vaccines have been performed. Since the clinical efficacy of HLA class I-restricted peptide vaccines is still poor, many researchers are mainly administering dendritic cell therapies. However, there have been few clinicals trials of cancer-specific immunotherapy for esophageal carcinomas. We have performed cancer vaccine therapy with SART-1 peptide and locoregional adoptive immunotherapy with activated autologous lymphocytes for patients with advanced esophageal carcinoma in a phase I and a phase I/II trial, respectively. The clinical responses were poor in the vaccine trial because of the rapid growth of esophageal cancers and the requirement for more than 2 months to activate and increase killer T cells after in vivo vaccination, while locoregional adoptive immunotherapy was effective for the treatment of esophageal cancers even in advanced stages with organ metastases. Based on these results, we think that a combination immunotherapy with adoptive immunotherapy and vaccine therapy is needed for the treatment of advanced esophageal carcinomas. 相似文献
40.
Daigo Komatsu Kazuma Ikeuchi Toshihisa Kojima Yasuhiko Takegami Takafumi Amano Masaki Tsuboi 《Laterality》2017,22(3):340-353
There are few reports of the laterality in radiological knee osteoarthritis (ROA). This study aimed to evaluate laterality in terms of the minimum joint space width (mJSW) and osteophyte areas (OFs) in a cross-sectorial general population screen and elucidate the association between laterality and risk of osteoarthritis. We enrolled 330 participants (mean age 64.6 years) and examined the presence of ROA (Kellgren–Lawrence grade?≧?2) laterality in terms of the mJSW and OF on the medial tibia using auto-measuring software. Moreover, we examined the association between laterality and leg dominance. The right and left medial mJSWs were 4.02?±?0.98?mm and 4.05?±?1.01?mm, respectively, showing no laterality; the laterals were also similar. The participants who had osteophytes ≥1?mm2 in the right, left, and bilateral knees were 15, 37, and 57 respectively, with osteophytes being significantly more common in the left knee. The OF was significantly larger in the left knee. Conversely, the medial and lateral mJSWs and OF did not differ according to leg dominance. The prevalence of ROA was higher and the OF was more pronounced in the left knee. However, the mJSW showed no laterality. Additionally, the mJSW and OF showed no differences according to leg dominance. 相似文献